Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock

Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common
                                    Stock

PR Newswire

SEATTLE, May 14, 2013

SEATTLE, May 14, 2013 /PRNewswire/ --Omeros Corporation (NASDAQ: OMER) today
reported that it closed the registered direct offering of 3,903,004 shares of
its common stock that was announced on May 9, 2013. The shares were sold at a
price of $4.14 per share, which represented a two percent premium over the
closing price on May 8, 2013. The shares were sold directly to affiliates of
RA Capital Management and other investors without an underwriter or placement
agent. Omeros received net proceeds from the offering of approximately $16.1
million, after deducting estimated offering expenses.

Omeros intends to use the net proceeds of the offering for general corporate
purposes, including expenses related to the potential commercialization of
OMS302 for intraocular lens replacement, as well as for research and
development expenses, such as funding planned clinical trials for its
OMS103HP, PDE10, MASP-2 and PDE7 programs. The net proceeds may also be used
to fund pre-clinical studies, capital expenditures, working capital and to
otherwise advance Omeros' potential products towards commercialization.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering,
developing and commercializing products targeting inflammation, coagulopathies
and disorders of the central nervous system. The Company's most clinically
advanced product candidates, OMS302 for lens replacement surgery and OMS103HP
for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform
designed to improve clinical outcomes of patients undergoing a wide range of
surgical and medical procedures. Omeros has five clinical development
programs. Omeros may also have the near-term capability, through its GPCR
program, to add a large number of new drug targets and their corresponding
compounds to the market. Behind its clinical candidates and GPCR platform,
Omeros is building a diverse pipeline of protein and small-molecule
preclinical programs targeting inflammation, coagulopathies and central
nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the
Private Securities Litigation Reform Act of 1995, which are subject to the
"safe harbor" created by those sections. These statements include, but are not
limited to, statements regarding the expected use of proceeds from the
registered direct offering. Forward-looking statements are based on
management's beliefs and assumptions and on information available to
management only as of the date of this press release. Omeros' actual results
could differ materially from those anticipated in these forward-looking
statements for many reasons, including, without limitation, the risks,
uncertainties and other factors described under the heading "Risk Factors" in
the Company's Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on May 9, 2013. Given these risks, uncertainties and other
factors, you should not place undue reliance on these forward-looking
statements, and the Company assumes no obligation to update these
forward-looking statements publicly, even if new information becomes available
in the future.

SOURCE Omeros Corporation

Contact: jennifer@cwcomm.org
 
Press spacebar to pause and continue. Press esc to stop.